Copertina

Diabetes remission in adults with cystic fibrosis commenced on Elexacaftor/Tezacaftor/Ivacaftor: A single center case‐series

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Shanal Kumar, Angela G. Matson
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Pediatric Pulmonology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Improving Pancreatic Function With Elexacaftor/Tezacaftor/Ivacaftor
di: Madison Pranske, et al.
Pubblicazione: (2026)

Codevelopment of a model of care for adults living with cystic fibrosis‐related diabetes
di: Shanal Kumar, et al.
Pubblicazione: (2024)

Crushing Elexacaftor/Tezacaftor/Ivacaftor Oral Granules for Gastrostomy Tube Administration
di: Alexander S. Kim, et al.
Pubblicazione: (2025)

Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Quality of Life in Children With Cystic Fibrosis
di: Sara Kümmerli, et al.
Pubblicazione: (2026)

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Microbiology and Antibiotic Utilization in People With Cystic Fibrosis
di: Cindy L. Williams, et al.
Pubblicazione: (2025)

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fecal Elastase‐1 in Children With Cystic Fibrosis
di: Senthilkumar Sankararaman, et al.
Pubblicazione: (2025)

Effects of Elexacaftor‐Tezacaftor‐Ivacaftor on Nasal and Sinus Symptoms in Children With Cystic Fibrosis
di: Guillaume Petit, et al.
Pubblicazione: (2025)

Papilledema in Children With Cystic Fibrosis Receiving Elexacaftor/Tezacaftor/Ivacaftor: A Multicenter Case Series
di: Charissa W. Kam, et al.
Pubblicazione: (2024)

Elexacaftor/Tezacaftor/Ivacaftor Treatment Accessibility and Mental Health: Reducing Anxiety in People With Cystic Fibrosis
di: Burcu Uzunoglu, et al.
Pubblicazione: (2025)

Lung clearance index (LCI2.5) changes after initiation of Elexacaftor/Tezacaftor/Ivacaftor in children with cystic fibrosis aged between 6 and 11 years: The “real‐world” differs from trial data
di: Don S. Urquhart, et al.
Pubblicazione: (2024)

Mental Health of Pediatric Patients with Cystic Fibrosis after 18 Months on Elexacaftor‐Tezacaftor‐Ivacaftor Therapy
di: Kimberly Pasley, et al.
Pubblicazione: (2024)

Real‐World Impact of Elexacaftor/Tezacaftor/Ivacaftor in Israeli Children Aged 2–6 With Cystic Fibrosis
di: Adi Dagan, et al.
Pubblicazione: (2026)

A Tale of Two Infants: Off‐Label Use of Elexacaftor/Tezacaftor/Ivacaftor in Early Cystic Fibrosis Treatment
di: Nour K. Kadouh, et al.
Pubblicazione: (2025)

The Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Biochemical Surrogates of Cystic Fibrosis Hepatobiliary Involvement: A Retrospective Cohort Study
di: Sasha‐Jane Abi‐Aad, et al.
Pubblicazione: (2026)

Body Image Perceptions and Elexacaftor/Tezacaftor/Ivacaftor (ETI) Use in Adolescents and Young Adults Living With Cystic Fibrosis
di: Emma R. Lyons, et al.
Pubblicazione: (2025)

Real World Adverse Effects of Elexacaftor/Tezacaftor/Ivacaftor in People With Cystic Fibrosis Ages 6–11 Years
di: Rebecca S. Pettit, et al.
Pubblicazione: (2025)

Relating Improvement in Gastrointestinal (CFAbd‐Score © ) and Sinonasal (SNOT) Symptoms During Therapy With Elexacaftor/Tezacaftor/Ivacaftor in CF Patients
di: Jochen G. Mainz, et al.
Pubblicazione: (2026)

Heterogeneity in Reported Side Effects Following Initiation of Elexacaftor‐Tezacaftor‐Ivacaftor: Experiences at a Quaternary CF Care Center
di: Lena Papadakis, et al.
Pubblicazione: (2024)

Respiratory Oscillometry and Multimodal Lung Function Assessment of Elexacaftor/Tezacaftor/Ivacaftor Response in Children and Young Adults With Cystic Fibrosis
di: Christos Kogias, et al.
Pubblicazione: (2026)

Variable Response to Elexacaftor/Tezacaftor/Ivacaftor in [L467F;F508del] Homozygous Patients: A Case Series
di: Meltem Akgül Erdal, et al.
Pubblicazione: (2026)

Multidimensional Impacts of Elexacaftor/Tezacaftor/Ivacaftor: Comparisons of Physical and Mental Health Providers' Observations in Cystic Fibrosis in Europe and the United States
di: Sonia Graziano, et al.
Pubblicazione: (2025)

Peripheral Muscle Function and Body Composition in People With Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor: A Cross‐Sectional Single‐Centre Study
di: Lauren J. Clayton, et al.
Pubblicazione: (2025)

Real‐World Improvements of Lung Clearance Index and Ventilation Distribution Efficiency in Children With Cystic Fibrosis After Elexacaftor/Tezacaftor/Ivacaftor Initiation
di: Esben Herborg Henriksen, et al.
Pubblicazione: (2025)

Effects of an Exercise Intervention on Exercise Capacity in Adults With Cystic Fibrosis: A Quasi‐Experimental Study Comparing Individuals Treated With and Without Elexacaftor/Tezacaftor/Ivacaftor
di: Wolfgang Gruber, et al.
Pubblicazione: (2025)

Elexacaftor/Tezacaftor/Ivacaftor Effect on a Patient With Rare Compound Heterozygous CFTR Splice Variant Genotype C.[1393‐1G>A;2988+1G>A]
di: Maria Moustaki, et al.
Pubblicazione: (2025)

Lung T1‐MRI and Multi‐Breath Washout Detect Longitudinal Changes in Children 6–11 Years Old After Beginning Elexacaftor/Tezacaftor/Ivacaftor (ETI) Therapy
di: Samya Z. Nasr, et al.
Pubblicazione: (2026)

The foregut in cystic fibrosis
di: Christopher Vélez, et al.
Pubblicazione: (2024)

Validation of the Integrated Palliative Care Outcome Scale (IPOS) in adults with cystic fibrosis
di: Anna M. Georgiopoulos, et al.
Pubblicazione: (2024)

The future of cystic fibrosis: A global perspective
di: Felix Ratjen
Pubblicazione: (2024)

Preferences and perspectives regarding telehealth exercise interventions for adults with cystic fibrosis: A qualitative study
di: Megan Poulsen, et al.
Pubblicazione: (2024)

Prevalence of cannabidiol use in persons with cystic fibrosis
di: Emma M. Tillman, et al.
Pubblicazione: (2024)

Time to be blunt: Substance use in cystic fibrosis
di: Sanaz Vaziri, et al.
Pubblicazione: (2024)

Predicting weight gain in patients with cystic fibrosis on triple combination modulator
di: Kelly L. Stewart, et al.
Pubblicazione: (2024)

A comparison of aminoglycoside antibiotic serum concentrations collected by peripheral veins and peripherally inserted central catheters in adults with cystic fibrosis
di: Sabrina J. Sherwood, et al.
Pubblicazione: (2024)

Successful treatment of Stenotrophomonas maltophilia with ceftazidime‐avibactam and aztreonam in an individual with cystic fibrosis: A case report
di: Stephanie Duehlmeyer, et al.
Pubblicazione: (2024)

Clinical evidence of pancreatic recovery in children with cystic fibrosis on ivacaftor
di: Sydney Walker, et al.
Pubblicazione: (2024)

Nutrition and behavioral health in cystic fibrosis: Eating and body image
di: Emma R. Lyons, et al.
Pubblicazione: (2024)

Adding fuel to the fire: The growing case for global access to cystic fibrosis transmembrane conductance regulator modulator therapy
di: Brenda M. Morrow, et al.
Pubblicazione: (2024)

Me, myself, and I: A systematic review of cystic fibrosis and self‐concept
di: Maggie Harrigan, et al.
Pubblicazione: (2024)

Disparities in elexacaftor/tezacaftor/ivacaftor initiation in the US cystic fibrosis population
di: Kamyron Jordan, et al.
Pubblicazione: (2024)